JETREA

This brand name is authorized in United States. It is also authorized in Australia, Austria, Croatia, Cyprus, Estonia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, UK.

Active ingredients

The drug JETREA contains one active pharmaceutical ingredient (API):

1	Ocriplasmin UNII 7V6HE3DM5A - OCRIPLASMIN
	Ocriplasmin has a proteolytic activity against protein components of the vitreous body and the vitreoretinal interface (VRI) (e.g. laminin, fibronectin and collagen) and aims to dissolve the protein matrix responsible for the abnormal vitreomacular adhesion (VMA).
	Read more about Ocriplasmin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
JETREA Concentrate for solution for injection	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01XA22		S Sensory organs → S01 Ophthalmologicals → S01X Other ophthalmologicals → S01XA Other ophthalmologicals
Discover more medicines within S01XA22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	11798Y
EE	Ravimiamet	1610075, 1684122
GB	Medicines & Healthcare Products Regulatory Agency	360251
IL	מִשְׂרַד הַבְּרִיאוּת	7598
IT	Agenzia del Farmaco	042736013, 042736025
LT	Valstybinė vaistų kontrolės tarnyba	1069744, 1076836
NL	Z-Index G-Standaard, PRK	106062
PL	Rejestru Produktów Leczniczych	100297103, 100344104
US	FDA, National Drug Code	24856-002